Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
3 July 2017
E-004456-17
Question for written answer
to the Commission
Rule 130
Jean-François Jalkh (ENF)

 Subject:  Production of antibiotics in Asia
 Answer(s) 

The website Euractiv has published the results of an investigation by researchers from Leipzig, which shows that some antibiotics sold in Germany are produced in India in what are described as alarming conditions likely to contribute to the development of pathogens resistant to most forms of treatment, and hence the risk of an epidemic. Pharmaceutical firms are contributing to the development of killer bacteria because they are not purifying drains in their immediate surroundings.

Water samples taken near factories in November 2016 showed a high concentration of antibiotics and fungicides. In fact, the greater the contact bacteria and pathogens have with the medicines designed to fight them, the more quickly they can adapt and become resistant. Ninety-five per cent of the samples collected by the research team, at 28 different sites in India, contained multi-resistant pathogens. It should be noted that the vast majority of German pharmaceutical firms have their antibiotics and fungicides manufactured in India under these conditions.

Does the Commission know about these practices and what does it plan to do to ensure adherence to standards required in the European Union?

Original language of question: FR 
Last updated: 17 July 2017Legal notice